A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.

Saved in:
Bibliographic Details
Title: A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Authors: Cescon DW; Princess Margaret Cancer Center, University Health Network and University of Toronto, Toronto, Ontario, Canada., Hilton J; Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada., Morales Murilo S; Lleida Biomedical Research Institute, Lleida, Spain., Layman RM; MD Anderson Cancer Center, Houston, Texas., Pluard T; Saint Luke's Cancer Institute, Kansas City, Missouri., Yeo B; Olivia Newton-John Cancer Research and Wellness Centre and Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia., Park IH; National Cancer Center, Goyang, Republic of South Korea.; Korea University Guro Hospital, Seoul, Republic of South Korea., Provencher L; CHU de Québec-Laval University, Québec City, Québec, Canada., Kim SB; Asan Medical Center, Seoul, Republic of South Korea., Im YH; Samsung Medical Center, Seoul, Republic of South Korea., Wyce A; GSK, Collegeville, Pennsylvania., Krishnatry AS; GSK, Collegeville, Pennsylvania., Hicks K; GSK, Collegeville, Pennsylvania., Zhang Q; GSK, Collegeville, Pennsylvania., Barbash O; GSK, Collegeville, Pennsylvania., Khaled A; GSK, Collegeville, Pennsylvania., Horner T; GSK, Collegeville, Pennsylvania., Dhar A; GSK, Collegeville, Pennsylvania., Oliveira M; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Sparano JA; Icahn School of Medicine, Tisch Cancer Institute, New York, New York (formerly Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York).
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jan 17; Vol. 30 (2), pp. 334-343.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-23-0133